Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma.

ABSTRACT: Hepatocellular carcinoma (HCC) is the most frequent primary liver tumor. As a result of advanced disease being often present at diagnosis, only a small percentage of patients are amenable to curative-intent treatment options such as surgical resection and liver transplantation. Systemic therapy consisting of tyrosine kinase inhibitors such as sorafenib had been used for over a decade with limited efficacy. More recently, treatment with immune checkpoint inhibitors has revolutionized the treatment landscape of various malignant tumors. With this shifting paradigm, recent data have demonstrated encouraging outcomes among patients with HCC. In particular, several trials have investigated the safety and efficacy of various immune checkpoint inhibitors (ICI) either as monotherapy or in the form

SUBMITTER: Machairas N 

PROVIDER: S-EPMC9025403 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature